Detection & monitoring type 2 Diabetes
by means of AGE Reading

More than 100 million people worldwide are affected by diabetes, but many are undiagnosed. This number will increase to 300 million people by year 2025, according to the World Health Organization (WHO). At least 80 % of these cases are type 2 diabetes, or Non-Insulin Dependent Diabetes Mellitus (NIDDM). This occurs fairly late in life, typically at 50 years or higher, although the age of onset is decreasing.

The main function of the AGE Reader is to give information on the amount of advanced glycation endproducts (AGE's) in the patient's tissue.

In combination with the standard measurement of the Lifeclinic kiosk a reliable detection of Diabetes Type 2 can be measured noninvasive by the Diagnoptics AGE Reader.

AGE's are key players in glycemic and oxidative stress and have been shown to be an important indicator of the cardiovascular risk.

The noninvasive measurement immediately offers valuable additional information, comfortably and safely within 30 seconds. The AGE Reader has been validated in several large-scale, clinical trials over the last few years involving 1000s of adults. For more information please visit www.age-reader.com or

download folder (pdf, 2 MB)

Though the use of the AGE Reader itself can be without the guidance of a medical professional, Lifeclinic Europe recommends to use the AGE Reader detection method not in isolation but always in the context and close cooperation with a controlled application approach.

| back |